Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Immunovia AB (IMMNOV) NPV

Sell:117.40 SEK Buy:118.00 SEK Change: 2.60 SEK (2.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:117.40 SEK
Buy:118.00 SEK
Change: 2.60 SEK (2.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:117.40 SEK
Buy:118.00 SEK
Change: 2.60 SEK (2.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

Contact details

Address:
Medicon Village, Scheelevagen 2
LUND
223 81
Sweden
Telephone:
+46 (46) 2756000
Website:
immunovia.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMMNOV
ISIN:
SE0006091997
Market cap:
2.65 billion SEK
Shares in issue:
22.63 million
Sector:
Health Care Equipment
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Carl Borrebaeck
    Chairman of the Board
  • Patrik Dahlen
    Chief Executive Officer
  • Hans Liljenborg
    Chief Financial Officer
  • Lotta Blomgren
    Operations Director
  • Michael Pettigrew
    Senior Vice President - Sales NA
  • Peter Schultz-Knappe
    Chief Technology Officer
  • Rolf Ehrnstrom
    Chief Scientific Officer
  • Linda Mellby
    Vice President Research & Development
  • Hans Pedersen
    Vice President - Business Development
  • Laura Chirica
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.